Objective. Previous studies show that arthralgia is the most common symptom experienced by Ebola virus disease (EVD) survivors. Nevertheless, specific analyses of rheumatological sequelea are still lacking.
Introduction
There have been several limited outbreaks of Ebola virus in Central Africa in the last decade, leading to many deaths but also leaving many survivors. The most recent outbreak started in South-Eastern Guinea in December 2013, before extending to Liberia and Sierra Leone [1] . By March 2016, 3811 people were infected in Guinea, with 1270 survivors. Symptoms experienced by Ebola virus disease (EVD) survivors have been previously reported [26] . These studies showed that arthralgia and myalgia were the most common symptoms among convalescents. A recent study of 277 survivors in Sierra Leone, surveyed 4 months after EVD, reported persistent arthralgia in 76% of patients [2] . Nevertheless, specific analyses of EVD survivors experiencing rheumatological sequelea are still lacking. In Guinea, we established a prospective cohort (the Postebogui cohort), aiming to assess the long-term clinical, immunological and virological outcomes of EVD survivors. In the present study, our aim was to select patients from the Postebogui cohort with arthralgia/myalgia in order to determine clinical features of rheumatological issues among EVD survivors.
Methods

Study population
The Postebogui study is a prospective, multicentre open cohort aiming to evaluate the long-term clinical, virological, psychological and socio-behavioural outcomes of EVD in survivors infected during the 201415 outbreak. Since March 2015, survivors >1 year of age and living in Guinea have been recruited at the Donka National Hospital in Conakry and the Prefectoral Hospital in Macenta for a 2-year follow-up.
Patients reporting joint or muscle pain were referred for a complete rheumatological examination. The Conakry local committee of the Postebogui cohort contacted patients before the visit by the rheumatologist. They invited to participate patients who had reported pain previously. All patients were volunteers and available for this substudy. Of the 216 participants included as of 22 October 2015 in Conakry, a subgroup of 44 patients suffering from musculoskeletal pain underwent a complete rheumatological examination during a week from 22 October to 27 October 2015 (Eborheum cohort).
Data were collected using a standardized questionnaire by clinicians trained for the study and entered into an electronic database. 
Musculoskeletal assessment
The same experienced rheumatologist examined all patients. Collected data included age, gender, body weight, height, the date of Ebola Treatment Centre (ETC) discharge, date of inclusion in the Postebogui cohort, pain duration, visual analog scale for pain (VAS), dry eyes or dry mouth symptoms, presence and intensity of fatigue, and the presence, distribution and number of current swollen or tender joints diagnosed by the physician and based on EULAR standardized methodology [7] . The physical examination included the standard evaluation of 18 tender point sites, and symmetrical distribution was evaluated for each site [8] . Inflammatory pain was considered if at least three of the following criteria were present: pain during the night or early morning, reduction of pain with activity, occurrence of pain at rest and morning stiffness of 530 min. Conversely, mechanical pain was considered if the patient presented at least three of the following criteria: occurrence of pain with activities and improvement at rest, no pain during the night and morning stiffness <30 min.
Psychological evaluation
At the inclusion in the Postebogui cohort, a psychological evaluation was performed in participants older than 20 years. The French 20-item Centre for Epidemiologic Studies Depression Scale (CES-D) was used to diagnose depression. The CES-D assesses the frequency of occurrence of symptoms during the past week on a four-point Likert scale, ranking from 0 = 'rarely or none of the time' to 3 = 'most or all of the time'. Total scores range from 0 to 60. Participants with a score >17 for men and >23 for women are considered to be depressed [9] .
Statistical analysis
Data were analysed using Fisher's exact test for categorical variables (presented as frequencies and percentages) and using a non-parametric MannWhitney U-test for continuous variables (presented as the median and interquartile range, IQR). We also investigated whether depression was associated with sustained musculoskeletal disorders by comparing patients in the Eborheum cohort with Postebogui patients who were not included in the cohort (using Fisher's exact test).
Results
Study population
Overall, 44 patients suffering from arthralgia or myalgia were examined by the same rheumatologist at the Donka National Hospital in Conakry (Table 1) . At the time of the analysis, 43 patients reported joint pain and one patient had myalgia without articular pain. Just over half (n = 27; 61%) were female, and the median age was 31.1 years (20.739.6). Median BMI was 23.4 kg/m 2 (20.427.8). Median time from ETC discharge to rheumatological examination was 8.8 months (7.011.2). Pain manifestations started after Ebola infection in all patients www.rheumatology.oxfordjournals.org except one, who had previous articular pain 6 months before EVD (mechanical back pain).
Among the remaining 172 patients in the Postebogui cohort who were not made part of the Eborheum cohort, we differentiated two groups (Table 1) : patients who reported rheumatic complaints since their inclusion in Postebogui cohort (group 1, n = 91) and those without any musculoskeletal pain experienced during the followup (group 2, n = 81). Patients included in the Eborheum cohort did not differ from patients who did not report musculoskeletal pain (group 2) in their time from post-ETC discharge to Postebogui inclusion, gender, height or CRP concentrations. Conversely, we observed significantly older patients in the Eborheum cohort (median 31.1 years old) vs group 2 (22.2 years old; P = 0.001) and heavier patients in the Eborheum cohort (median 62.0 kg) vs group 2 (56 kg; P = 0.011).
Characteristics of rheumatic disorders
Morning stiffness was present in 75% of patients (n = 33), with a median stiffness duration of 60 min. Forty-five per cent of patients reported only mechanical pain, 9% only inflammatory pain, and 45% reported experiencing both mechanical and inflammatory pain. Thirty-three patients (77%) had low back pain, and all patients had at least one painful peripheral joint. Joint pain VAS was high, with a median score of 60 mm (5080). Fatigue was present in 37 patients (84%), again with a high median VAS score of 60 mm (5080). Respectively, 16 (37%) and 8 patients (20%) reported dry mouth and dry eye symptoms. Myalgias were present in 61% of patients (n = 27), with muscle weakness for 18 patients.
A complete pain distribution is detailed in Table 2 . We observed synovitis in four patients and tenosynovitis in two other patients (finger flexor and ankle). Large joints were more frequently affected than small joints (73 vs 41%). Oligo-and polyarticular presentations were similar (41 vs 59%), and symmetrical pain distribution between all peripheral joints was frequent (4381%; data not shown).
Furthermore, 36 patients (82%) had at least one painful 18-tender point count, most of whom had extensive pain (n = 19) and symmetrical distribution (91%).
Regarding suspected diagnosis, three patients reported monoarthritis attributable to septic infection (not documented), and two patients reported inflammatory arthralgia without synovitis. In five patients with inflammatory back pain, undifferentiated spondyloarthritis was possible. Non-specific musculoskeletal disorders (n = 26; 59%) were most often found. The second main diagnosis was mechanical spine back pain (n = 23; 52%).
Association between chronic musculoskeletal pain and psychological state Among adults >20 years of age who responded to the psychological CES-D questionnaire (n = 142), 42% were considered as depressed in the Eborheum cohort (n = 14/33), vs 11% in the remaining Postebogui group (n = 12/109; P < 0.001).
Discussion
Our study is an in-depth analysis of rheumatic complaints (myalgia, arthralgia and back pain) among a selected sample of EVD survivors. To our knowledge, this is the first complete examination of EVD survivors by a specialist in rheumatology. Large joint pain and symmetrical localization were characteristic among patients in the Eborheum cohort, consistent with previous suggestions from the 1995 Kikwit outbreak [5] . We observed slightly more polyarticular than oligoarticular forms, a pattern in contrast to observations from a cohort of EVD survivors in Sierra Leone, which found arthralgia in 210/277 patients (76%) and more oligoarticular forms [2] . Such discrepancies could be explained by methodological differences, as many previous studies relied solely on self-reported pain in questionnaires, without physical examination [4, 5, 10, 11] , or on physical examinations not carried out by a specialist in rheumatology [2, 3, 6] . The joint symptoms observed in the Eborheum cohort seem not to be specific, and may share similarities with other infectious diseases, such as HIV, EBV or HCV. In contrast to infection with the alpha virus Chikungunya [12] , we did not identify symmetrical synovitis mimicking RA. The underlying pathophysiological mechanisms of these post-infectious complications remain unknown.
Patients in the Eborheum cohort were nearly six times more likely to show signs of depression than other EVD survivors. The high percentage of depressed patients in the cohort is not surprising, because chronic pain is known to generate psychological suffering and can lead to depression. The observation underscores the need to consider the impact of pain symptoms among EVD survivors. In particular, we found a high number of widespread painful tender points (82%). Added to the depression profile, it may recall the FM syndrome as previously observed with other viral infections [13] .
Several limitations of this investigation should be acknowledged. We did not manage to perform a physical examination of all the patients suffering from arthralgia/ myalgia in the Postebogui cohort, which may result in a selection bias in the analysis. However, we compared baseline main demographic and clinical features in the Eborheum cohort with remaining EVD patients in the Postebogui cohort. We found no significant differences comparing the Eborheum cohort with patients reporting rheumatic complaints at the inclusion (group 1, n = 91) or those without any rheumatic pain disorders during the follow-up (group 2, n = 81), with the exception that the median age and weight in the Eborheum cohort were significantly greater than those in group 2. Moreover, we analysed a small number of patients compared with various recent cohorts [2, 6] , and we did not have a comparison group of patients to generate data on the prevalence of musculoskeletal disorders in EVD survivors.
To conclude, we provided the first accurate description by a specialist of rheumatic issues reported by EVD survivors. Compared with some other viral infections, synovitis seems rare. Furthermore, our study showed a strong correlation between pain and depression, highlighting the importance and impact of pain symptoms among EVD survivors. These interesting findings need to be confirmed in a larger sample and by a prospective follow-up of the patients included in the cohort.
